Objective: There have been no systematic reviews, let alone meta-analyses, of randomized controlled trials (RCTs) comparing tongxinluo capsule (TXL) and beta-blockers in treating angina pectoris. This study aimed to evaluate the efficacy of TXL and beta-blockers in treating angina pectoris by a meta-analysis of eligible RCTs. Methods: The RCTs comparing TXL with beta-blockers (including metoprolol) in treating angina pectoris were searched and retrieved from databases including PubMed, Chinese National Knowledge Infrastructure, and WanFang Data. Eligible RCTs were selected according to prespecified criteria. Meta-analysis was performed on the odds ratios (OR) of symptomatic and electrocardiographic (ECG) improvements after treatment. Subgroup analysis, sensitivity analysis, meta-regression, and publication biases analysis were conducted to evaluate the robustness of the results. Results: Seventy-three RCTs published between 2000 and 2014 with 7424 participants were eligible. Overall ORs comparing TXL with beta-blockers were 3.40 (95% confidence interval [CI], 2.97-3.89; p < 0.0001) for symptomatic improvement and 2.63 (95% CI, 2.29-3.02; p < 0.0001) for ECG improvement. Subgroup analysis and sensitivity analysis found no statistically significant dependence of overall ORs on specific study characteristics except efficacy criteria. Meta-regression found no significant except sample sizes for data on symptomatic improvement. Publication biases were statistically significant. Conclusion: TXL seems to be more effective than beta-blockers in treating angina pectoris, on the basis of the eligible RCTs. Further RCTs are warranted to reduce publication bias and verify efficacy.
Introduction
A ngina pectoris, a symptom of coronary heart disease (CHD), is pain or discomfort in the chest due to ischemia of the heart muscle during obstruction or spasm of the coronary arteries. 1 Conventional anti-anginal drugs include four categories: beta-blockers (e.g., metoprolol), calcium channel blockers (e.g., verapamil), nitrates (e.g., isosorbide dinitrate), and potassium channel activators (e.g., nicorandil). Betablockers are the recommended first-line drug for relieving symptoms of stable angina. 2 Beta-blockers improve oxygen supply and demand balance through reduction of heart rates and blood pressures, decreases in systolic stress and contractility, prolongation of diastole, enhancement of coronary flows. 2 Chinese patent medicines, including danshen dripping pill, di'ao xinxuekang capsule, and tongxinluo capsule (TXL) were found to be more effective than starting doses of isosorbide dinitrate, as shown in a direct meta-analysis. [3] [4] [5] It was interesting that indirect comparisons through metaanalysis found that TXL was even more effective than Danshen dripping pill. 6 TXL was approved as a new drug (drug approval number Z19980015) by the Ministry of Health of China in 1996.
vessels. Eupolyphaga species reduces left ventricular enddiastolic pressure and heart rate. 9 As a result, TXL enhances myocardial contractility, dilates blood vessels, reduces cardiac afterload, and improves myocardial blood supply. 10 Previous systematic reviews studied beta-blockers or TXL in treating angina pectoris but did not compare them head-to-head. Because hundreds of randomized controlled trials (RCTs) comparing TXL with beta-blockers have been published, a systematic review and meta-analysis would be in great demand to synthesize evidence from those RCTs. This study aims to conduct a meta-analysis to compare the efficacy of TXL with that of beta-blockers in treating angina pectoris.
Materials and Methods
The design, implementation, analysis, and reporting of this meta-analysis were in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. 11 
Search strategies
Databases including PubMed, MEDLINE, Cochrane Library, ScienceDirect, China National Knowledge Infrastructure, WanFang Data, China Master Theses Full-text Database, and China Doctor Dissertations Full-text Database were searched for RCTs on the efficacy of TXL in treating angina pectoris between the inception dates of the databases and 2014 (last search was performed on May 27, 2013) . The following search strategy with keywords was used in searching PubMed and other English-language databases:
The following search strategy was used in searching the Chinese National Knowledge Infrastructure and other Chinese databases:
where IN, AND, OR are logical operators for database search.
Study selection
Inclusion criteria for study selection were the following: (1) the participants had and were being treated for angina pectoris, (2) the study design was an RCT; (3) the RCT compared TXL with beta-blockers, and (4) the follow-up period was no less than 4 weeks. Exclusion criteria were the following: (1) duplicated or redundant reports on the same study, (2) studies did not include symptomatic improvement as a major outcome, and (3) the studies were inconsistent or there were discrepancies between methods and results. Figure 1 shows the flow for study selection according to the inclusion and exclusion criteria.
Data extraction and quality assessment
For each of the included studies, the following data were extracted: (1) publication year, (2) sample characteristics, (3) follow-up periods, (4) baseline characteristics of participants between groups, (5) sample sizes, (6) outcome measures, including symptomatic and electrocardiography (ECG) improvement, (7) drug treatments in experimental and control groups, and (8) frequencies of adverse events. The quality of the included studies was assessed according to the Cochrane Collaboration's tool for assessing risk of bias, 12 the Jadad scale, 13 and the refined version of the Jadad scale, the M scale. 3 The Cochrane Collaboration's tool to assess the risk of bias comprises six domains assessed as low risk, high risk, and unclear risk: generation of the allocation sequence, concealment of the allocation sequence, blinding, incomplete outcome data, selective outcome reporting, and other biases. 12 The Jadad scale assesses the methodologic quality of a clinical trial in randomization, blinding, and withdrawals and dropouts. 13 The M scale comprises the Jadad scale plus two additional items: the use of group baselines comparison and the adverse effects description. 14 The quality of evidence was assessed by the grading of recommendation, assessment, development, and
Results of the database search and study selection process. IHD, ischemic heart disease; RCT, randomized controlled trial. evaluation (GRADE) method 14 and was classified into four categories: high, moderate, low, and very low. 15 Efficacy criteria for symptomatic and ECG improvements For efficacy evaluation, symptomatic improvements should achieve at least 50% (basic) or 80% (significant) reduction in frequency, duration, and severity of angina pain and palpitation. ECG improvements should achieve (1) at least 0.05 mV lowering at the ST segment on ECG (basic) or (2) nearly normal (significant) performance during an exercise test according to the American College of Cardiology/American Heart Association guidelines. 16 
Statistical analysis
Overall effect sizes were represented in odds ratios (OR) 17 and 95% confidence intervals (CI). 18 Meta-analysis used the random-effects model, with heterogeneity assessed by chisquare and I 2 tests. 19 Subgroup and sensitivity analyses were conducted according to the publication years, follow-up periods, sample sizes, study quality scores, efficacy criteria, and treatments. Meta-regression 20 was performed to determine possible relationships between the overall effects and such factors as sample sizes, follow-up periods, M scores, and publication years. Funnel plot, 21 the Egger test, 22 and the Begg test 23 were used to assess publication bias. The trimand-fill method 24 was used to correct funnel plot asymmetry arising from publication bias. Information about adverse events (AEs) of RCTs, including nonreported AEs and types and frequencies of AEs reported, was tabulated for evaluation. The Spearman rank correlation test was performed to determine possible correlation between ORs of symptomatic and ECG improvement. The Mann-Whitney-Wilcoxon test was used to compare two subgroups. The Kruskal-Wallis test was used to compare multiple subgroups at the same time. Bonferroni correction of p-values was performed for multiple comparisons. All statistical analyses were performed with statistical software R. 25 The ''metafor'' 26 package was used in R for meta-analysis. Any p-values below 0.05 were considered to represent statistically significant findings.
Results

Study selection and characteristics
The search of databases found 2328 records. According to the inclusion and exclusion criteria, 78 RCTs 27 -104 were included in meta-analysis. Figure 1 shows the process of study selection. Figure  2 . The overall quality of the included studies were at low risk of bias.
Overall effect sizes
Overall OR of symptomatic improvement was 3.40 (95% CI, 2.97-3.89; Z = 17.69; p < 0.0001) with non-significant heterogeneity (I 2 = 0%, p = 0.9999) among the 78 studies with an outcome of symptomatic improvement ( Fig. 3 and Table 2 ). Figure 4 and Table 3 show that the overall OR of ECG improvement was 2.63 (95% CI, 2.29-3.02; Z = 13.85; p < 0.0001) with non-significant heterogeneity (I 2 = 0%; p = 0.8602). Both ORs for symptomatic improvement and ECG improvement indicated that TXL was more effective than beta-blockers for treating angina pectoris. The Spearman correlation between symptomatic improvement and ECG improvement in ORs was statistically significant (rho = 0.6193; p < 0.0001), indicating that symptomatic improvement and ECG improvement corroborated with each other to provide positive evidence. According to GRADE in Table 4 , the quality of evidence for overall effect sizes with data on symptomatic improvement was classified as high and the quality of evidence for overall effect sizes with ECG data was classified as moderate.
Subgroup and sensitivity analyses
The ORs of the subgroups for both symptomatic improvement (Table 2 ) and ECG improvement (Table 3) were compared according to study characteristics, including M scores (£3 or >3), sample sizes (<95 or ‡95), number of authors (1 or >1), years of publication (before or after January 1, 2008), reports of trial dates (yes or no), baseline comparison of participants (yes or no), reports of AEs (yes or no), and follow-up periods (28 days or >28 days); different interventions in the control group (monotherapy with When the improvement criteria were raised to the significant level from the basic level, the overall results remained effective (i.e., OR > 1.9) and statistically significant. The overall OR for symptomatic improvement decreased from 3.40 to 1.90 (95% CI, 1.72-2.10; Z = 12.70; p < 0.0001). The overall OR for ECG improvement decreased from 2.63 to 1.95 (95% CI, 1.71-2.22; Z = 10.04; p < 0.0001). This sensitivity test for symptomatic improvement and ECG improvement showed that the overall efficacy of TXL over betablockers was still significantly positive even when the improvement standards were raised. There was a statistically significant correlation between the significant improvement in ORs for symptomatic and ECG outcomes (rho = 0.3083; p = 0.0350). The quality of evidence for overall effect sizes with data on symptomatic improvement and ECG improvement was classified as moderate when the improvement criteria were raised to the significant level (Table 4) . There was no statistically significant difference between ORs of other subgroups. The agreement among the subgroup analysis results on different study characteristics indicated that the efficacies of TXL versus beta-blockers with all included studies were consistently stable.
Meta-regression
Meta-regression was performed between ORs and study characteristics. Table 5 shows no statistically significant or high correlation between efficacies of TXL over betablockers and study characteristics.
Publication bias
Funnel plots (Fig. 5) show the presence of publication biases among the included studies. Both the Egger test (symptomatic improvement: t = 0.2209, p = 0.0044; ECG improvement: t = 0.1626, p = 0.1084) and the Begg test (symptomatic improvement: Z = 2.8375, p = 0.0045; ECG improvement: z = 1.8697, p = 0.0615) indicated statistically significant publication biases. Use of the trim-and-fill method found that on the left side of the funnel plots there should have been 23 missing studies for symptomatic improvement and 10 missing studies for ECG improvement. Z and p-value (effect) evaluated the statistics of overall effect; I 2 , chi-square, and p-value for heterogeneity were computed to assess heterogeneity.
RCT, randomized controlled trial; OR, odds ratio; CI, confidence interval; CM, Chinese medicine; df, degrees of freedom. On the basis of data for symptomatic improvement, the OR was 2.95 (95% CI, 2.70-3.20; Z = 17.14; p < 0.0001) and heterogeneity was not statistically significant (Q = 65.32; p = 0.9971) after trim-and-fill adjustment. On the basis of ECG data, the OR was 2.34 (95% CI, 2.08-2.59; Z = 13.01; p < 0.0001) and heterogeneity was not statistically significant (Q = 63.56; p = 0.2275) after trim-and-fill adjustment.
Adverse events Table 6 listed the information about AEs. All AEs were minor or well tolerated; none caused dropouts except in one study, 45 in which two participants dropped out because of severe stomachache and abdominal distention. Nineteen studies reported that 56 participants in total had epigastric discomfort. Epigastric discomfort, flush, and headache were the top three AEs reported in the control groups. Thirty studies reported AEs and 42 studies did not report any AEs. The other five studies reported that 45 participants in total had epigastric discomfort. Overall, AEs of TXL were more frequent and severe than those of the control drugs.
Discussion
This analysis of 78 RCTs with 3812 participants in a treatment group and 3612 participants in a control group is the first PRISMA-compliant systematic review on the efficacy of TXL versus beta-blockers in treating angina pectoris. Overall ORs of symptomatic improvement and ECG improvement were 3.40 (95% CI, 2.97-3.89; Z = 17.69; p < 0.0001) and 2.63 (95% CI, 2.29-3.02; Z = 13.85; p < 0.0001), respectively. There was no significant heterogeneity among the 78 RCTs with data on symptomatic improvement (I 2 = 0%; p = 0.9999) and the 47 RCTs with data on ECG improvement (I 2 = 0%; p = 0.8526). Subgroup and sensitivity analyses on various features, such as study quality, sample sizes, follow-up periods, improvement criteria, and interventions, demonstrated that the efficacy findings were consistent. Meta-regression analysis showed no significant correlations between the selected features and overall efficacies. The Egger test, Begg test, and trim-andfill method found significant publication biases. After trimand-fill adjustment to cope with publication biases, the adjusted overall efficacy of TXL was still more effective than that of beta-blockers in treating angina pectoris.
Although the efficacy of TXL was improved as the daily dosages increase (6 pills, 9 pills, and 12 pills) for both symptomatic improvement (OR, 2.99, 3.20, and 3.60) and ECG improvement (OR, 3.29, 2.30, and 2.70) as outcome measures (Tables 2 and 3 Low quality of the included RCTs is a major limitation in this meta-analysis, although the overall findings were consistent with those of previous studies. [105] [106] [107] [108] While all studies were described as RCTs, only 6 studies 44, 66, 70, 82, 97, 98 used randomization procedures. Two studies 31, 85 were described as single blind. Only one RCT 44 clearly reported having dropouts. The mean Jadad score was 2.10 (median, 2.00; 95% CI, 2.04-2.17) and the mean M score was 3.42 (median, 3.00; 95% CI, 3.27-3.58). As such, high-quality RCTs would be necessary for this meta-analysis to draw a positive conclusion.
All included RCTs were conducted in China and reported in Chinese journals. The follow-up period of 53 RCTs was 28 days and the mean follow-up period of 78 RCTs was 42 days. Such short follow-up periods for patients with angina pectoris could not support the efficacy of longer treatment with TXL. The mean sample size of 95 was small. Thirtyeight RCTs did not report AEs at all, and others did not report AEs formally.
In conclusion, TXL seems to be more effective than betablockers in treating angina pectoris, according to the eligible RCTs. Further RCTs are warranted to reduce publication bias and verify efficacy. The other five RCTs reported 45 participants with epigastric discomfort.
NR, not reported.
